As of today, gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib are all FDA-approved first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations (Table 1). Here, EGFR is linked to non-small cell lung carcinoma.